全文获取类型
收费全文 | 1128219篇 |
免费 | 78488篇 |
国内免费 | 5433篇 |
专业分类
耳鼻咽喉 | 15359篇 |
儿科学 | 35074篇 |
妇产科学 | 29178篇 |
基础医学 | 159683篇 |
口腔科学 | 30557篇 |
临床医学 | 102587篇 |
内科学 | 211388篇 |
皮肤病学 | 24853篇 |
神经病学 | 84158篇 |
特种医学 | 44972篇 |
外国民族医学 | 243篇 |
外科学 | 168249篇 |
综合类 | 31999篇 |
现状与发展 | 20篇 |
一般理论 | 264篇 |
预防医学 | 78250篇 |
眼科学 | 26285篇 |
药学 | 92118篇 |
45篇 | |
中国医学 | 6287篇 |
肿瘤学 | 70571篇 |
出版年
2021年 | 10731篇 |
2019年 | 9610篇 |
2018年 | 13378篇 |
2017年 | 10677篇 |
2016年 | 11814篇 |
2015年 | 13953篇 |
2014年 | 18573篇 |
2013年 | 24918篇 |
2012年 | 34605篇 |
2011年 | 36857篇 |
2010年 | 21605篇 |
2009年 | 20026篇 |
2008年 | 32718篇 |
2007年 | 34838篇 |
2006年 | 35508篇 |
2005年 | 33807篇 |
2004年 | 31543篇 |
2003年 | 30259篇 |
2002年 | 28974篇 |
2001年 | 61151篇 |
2000年 | 62679篇 |
1999年 | 52176篇 |
1998年 | 13319篇 |
1997年 | 11824篇 |
1996年 | 11651篇 |
1995年 | 10928篇 |
1994年 | 9851篇 |
1993年 | 9164篇 |
1992年 | 38160篇 |
1991年 | 36568篇 |
1990年 | 36021篇 |
1989年 | 34509篇 |
1988年 | 31078篇 |
1987年 | 30146篇 |
1986年 | 28350篇 |
1985年 | 26545篇 |
1984年 | 19229篇 |
1983年 | 16153篇 |
1982年 | 8839篇 |
1979年 | 17041篇 |
1978年 | 11404篇 |
1977年 | 10231篇 |
1976年 | 8837篇 |
1975年 | 10068篇 |
1974年 | 11652篇 |
1973年 | 11275篇 |
1972年 | 10754篇 |
1971年 | 10092篇 |
1970年 | 9252篇 |
1969年 | 8938篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
12.
13.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
15.
目的 探讨低危单胎的足月妊娠自然临产后,潜伏期脑胎盘率(CPR)对预测新生儿不良结局的价值。方法 选取2018年1月至2021年3月我院住院临产分娩的673例孕妇为研究对象,测量胎儿大脑中动脉、脐动脉血流参数,获得分娩结局及新生儿结局。参考既往研究得出的不同孕周CPR正常参考值百分位作为分组指标(CPR≤10%参考值定为低CPR)。比较低CPR组(72例)与正常CPR组(601例)两组妊娠结局、新生儿不良结局。结果 低CPR组与正常CPR组在孕妇年龄、孕龄、产次、孕期体质量增长、总产程、新生儿体质量的构成上差异均无统计学意义(P>0.05)。低CPR组因胎儿窘迫行剖宫产或助产发生率、新生儿任一不良结局发生率、新生儿不良结局率均高于正常CPR组,差异均有统计学意义(P<0.05)。低CPR预测新生儿不良结局的准确率为89.5%(602/673),敏感度为51.7%(15/29),特异度为91.1%(587/644)。结论 本研究数据显示,对于无并发症及合并症、低风险的单胎足月妊娠,潜伏期低CPR与新生儿不良结局相关。 相似文献
16.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
17.
18.
Malunguja Gisandu K. Devi Ashalata 《Proceedings of the National Academy of Sciences, India. Section B.》2022,92(1):105-120
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences - Heavy metal concentrations in surface soils of Reserved Forests (RFs) have a significant impact on... 相似文献
19.
Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder. 相似文献
20.
Purnima Gogoi Geetika Kaur Nikhlesh K Singh 《World journal of gastroenterology : WJG》2022,28(46):6497-6511
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related mortality in the United States. Across the globe, people in the age group older than 50 are at a higher risk of CRC. Genetic and environmental risk factors play a significant role in the development of CRC. If detected early, CRC is preventable and treatable. Currently, available screening methods and therapies for CRC treatment reduce the incidence rate among the population, but the micrometastasis of cancer may lead to recurrence. Therefore, the challenge is to develop an alternative therapy to overcome this complication. Nanotechnology plays a vital role in cancer treatment and offers targeted chemotherapies directly and selectively to cancer cells, with enhanced therapeutic efficacy. Additionally, nanotechnology elevates the chances of patient survival in comparison to traditional chemotherapies. The potential of nanoparticles includes that they may be used simultaneously for diagnosis and treatment. These exciting properties of nanoparticles have enticed researchers worldwide to unveil their use in early CRC detection and as effective treatment. This review discusses contemporary methods of CRC screening and therapies for CRC treatment, while the primary focus is on the theranostic approach of nanotechnology in CRC treatment and its prospects. In addition, this review aims to provide knowledge on the advancement of nanotechnology in CRC and as a starting point for researchers to think about new therapeutic approaches using nanotechnology. 相似文献